Jounce Therapeutics is seeking an experienced translational immunologist to join the Translational
Exploratory and Clinical Immunology team and contribute to the development of novel cancer
immunotherapies. The successful candidate will be responsible for managing multiple aspects of
biomarker assays in on-going clinical trials. They will be applying Flow Cytometry and other
immunoassays to develop and execute on a predicative and pharmacodynamic biomarker strategy. As
part of a multi-disciplinary team, they will be expected to proactively interact with project teams, external
collaborators and drive lab-based research to bring best-in-class biomarker strategies to Jounce clinical
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment
decisions on the basis of race, color, national origin, age, physical or mental disability, marital status,
religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants
should be legally entitled to work for any employer in the U.S.
To apply, please visit https://careers-jouncetx.icims.com/.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor
associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.